PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests".

MLA

Panza, Francesca, et al. “PRESTIGIO RING ‘a 59-Year-Old Man with Multidrug Resistant HIV-1 Infection Failing a Regimen Including Dolutegravir, Rilpivirine, Atazanavir/Cobicistat: Successful Treatment Tailoring Based on Genotypic and Phenotypic Resistance Tests.’” The New Microbiologica, vol. 47, no. 1, May 2024, pp. 116–22. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=38700893&authtype=sso&custid=ns315887.

APA

Panza, F., Saladini, F., Bartolini, N., Gianmarino, F., Montagnani, F., Spagnuolo, V., Tumbarello, M., Santoro, M. M., Castagna, A., Zazzi, M., & Fabbiani, M. (2024). PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests.” The New Microbiologica, 47(1), 116–122.

Chicago

Panza, Francesca, Francesco Saladini, Niccolò Bartolini, Federica Gianmarino, Francesca Montagnani, Vincenzo Spagnuolo, Mario Tumbarello, et al. 2024. “PRESTIGIO RING ‘a 59-Year-Old Man with Multidrug Resistant HIV-1 Infection Failing a Regimen Including Dolutegravir, Rilpivirine, Atazanavir/Cobicistat: Successful Treatment Tailoring Based on Genotypic and Phenotypic Resistance Tests.’” The New Microbiologica 47 (1): 116–22. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=38700893&authtype=sso&custid=ns315887.